Wells Fargo’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Wells Fargo’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,296	Closed	-$627	–	7804
2023 Q2	$627	Hold	3,296	–	–	﹤0.01%	6439
2023 Q1	$1.12K	Buy	3,296 +200	+6%	+$81	﹤0.01%	6346
2022 Q4	$1K	Sell	3,096 -11,397	-79%	-$4.13K	﹤0.01%	6186
2022 Q3	$6K	Buy	+14,493	New	+$5.76K	﹤0.01%	5879
2022 Q1	–	Sell	-7,478	Closed	-$10K	–	8150
2021 Q4	$10K	Hold	7,478	–	–	﹤0.01%	6555
2021 Q3	$15K	Hold	7,478	–	–	﹤0.01%	6081
2021 Q2	$12K	Sell	7,478 -220,111	-97%	-$408K	﹤0.01%	6094
2021 Q1	$506K	Buy	227,589 +191,669	+534%	+$505K	﹤0.01%	4677
2020 Q4	$90K	Buy	35,920 +11,175	+45%	+$24.7K	﹤0.01%	5404
2020 Q3	$61K	Buy	24,745 +3,177	+15%	+$9.25K	﹤0.01%	5445
2020 Q2	$76K	Buy	+21,568	New	+$68.2K	﹤0.01%	5351
2019 Q3	–	Sell	-2,279	Closed	-$4K	–	6839
2019 Q2	$4K	Sell	2,279 -12,164	-84%	-$21.3K	﹤0.01%	6091
2019 Q1	$28K	Sell	14,443 -4	-0%	-$8	﹤0.01%	5447
2018 Q4	$19K	Sell	14,447 -2,567	-15%	-$4.7K	﹤0.01%	5792
2018 Q3	$42K	Sell	17,014 -8,169	-32%	-$24.1K	﹤0.01%	5645
2018 Q2	$84K	Buy	25,183 +10,687	+74%	+$41.1K	﹤0.01%	5448
2018 Q1	$61K	Buy	14,496 +5,193	+56%	+$18K	﹤0.01%	5500
2017 Q4	$30K	Buy	9,303 +6,124	+193%	+$22.3K	﹤0.01%	5693
2017 Q3	$12K	Buy	3,179 +2,129	+203%	+$8.07K	﹤0.01%	5841
2017 Q2	$4K	Hold	1,050	–	–	﹤0.01%	5974
2017 Q1	$3K	Hold	1,050	–	–	﹤0.01%	6129
2016 Q4	$3K	Hold	1,050	–	–	﹤0.01%	6058
2016 Q3	$3K	Sell	1,050 -3,000	-74%	-$9.81K	﹤0.01%	6014
2016 Q2	$13K	Hold	4,050	–	–	﹤0.01%	5609
2016 Q1	$10K	Hold	4,050	–	–	﹤0.01%	5698
2015 Q4	$13K	Hold	4,050	–	–	﹤0.01%	5681
2015 Q3	$14K	Hold	4,050	–	–	﹤0.01%	5639
2015 Q2	$5K	Hold	4,050	–	–	﹤0.01%	6030
2015 Q1	$3K	Hold	4,050	–	–	﹤0.01%	5931
2014 Q4	$2K	Sell	4,050 -20,180	-83%	-$43K	﹤0.01%	6035
2014 Q3	$105K	Sell	24,230 -3,000	-11%	-$14.7K	﹤0.01%	4643
2014 Q2	$135K	Buy	27,230 +3,230	+13%	+$16.6K	﹤0.01%	4553
2014 Q1	$131K	Buy	24,000 +23,000	+2,300%	+$133K	﹤0.01%	4536
2013 Q4	$6K	Hold	1,000	–	–	﹤0.01%	5324
2013 Q3	$7K	Hold	1,000	–	–	﹤0.01%	5212
2013 Q2	$5K	Buy	+1,000	New	+$5.07K	﹤0.01%	5225

Other funds holding NYMX

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

FCFC

First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

CAM

Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return

ODIJL

One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

Wells Fargo's NYMX Position: Q3 2023 in Review

Wells Fargo sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 3,296 shares — an estimated $627 sold.

Wells Fargo first reported a position in NYMX in Q2 2013 and held it in 36 quarters. The position peaked at $506K in Q1 2021. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

Wells Fargo reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
Wells Fargo sold 3,296 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $627.
Wells Fargo first reported a position in Nymox Pharmaceutical Corp in Q2 2013 and held it in 36 quarters.
Wells Fargo's Nymox Pharmaceutical Corp position peaked at $506K in Q1 2021.
5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.